Dancann Pharma

The newly revised legislative proposal (L135) was published on February 6 and is scheduled for its first reading on February 21, 2025.

The Company considers it essential to make these observations and proposals publicly available to ensure the broadest possible understanding of the proposed legislation and the challenges faced by both DanCann Pharma and the wider industry on a daily basis.

CEO Jeppe Krog Rasmussen comments:

"It is absolutely crucial to highlight these issues so that we can create consensus around our industry and ensure fair and harmonized regulatory frameworks across the various categories within our field. Unfortunately, the legislative proposal contains far too many loose ends - something we sincerely hope will be addressed and improved."

"We seek to provide the general public with insight into the challenges we encounter. We have nothing to hide - only everything to gain. Ultimately, our goal is to secure the best possible outcome for our stakeholders, including patients and investors."

"This is a highly niche area that requires significant time and effort to fully comprehend. In our consultation response, we have aimed to summarize the key aspects of the issue, in the hope of fostering a deeper understanding among all relevant stakeholders, including those directly impacted and beyond."

The consultation response exclusively reflects the views and positions of the DanCann Pharma Group, including its subsidiary, CannGros ApS.

Attached to this release are the following documents (in Danish):

• DanCann Pharma: Evaluering med kommentarer og anbefalinger
• DanCann Pharma: Evaluering med kommentarer og anbefalinger (resumé)
• DanCann Pharma: Spørgsmål til Indenrigs- og Sundhedsministeriet
• SUM: "L 135 Forslag til lov om ændring af lov om forsøgsordning med medicinsk cannabis og om ordning for dyrkning, fremstilling m.v. af medicinsk cannabis. (Permanent ordning med medicinsk cannabis og genfremsættelse efter notifikation for EU-Kommissionen)"
• SUM: Kommenteret Høringsnotat (Sundhedsudvalget 2024-25 - L 135 - Bilag 1 - Offentligt)
• SUM: Høringssvar (Sundhedsudvalget 2024-25 - L 135 - Bilag 1 - Offentligt)

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, visit: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.